Argenx's stock opened 8.9% up after a Phase III trial of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis met its primary endpoint.
Abigail Beaney is the editor of Clinical Trials Arena. With expertise in clinical trial regulation, trial design, and cell and gene therapies, she has covered a wide range of topics within medicine and healthcare, including neurodegenerative, infectious, and metabolic diseases. Abigail's work has been featured in notable publications such as Pharmaceutical-Technology, Yahoo Finance, and Medical Device Network.













